溶瘤病毒在肺癌治疗中的研究进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

林希 , XIANG Liping , YANG Yi ,  HUANG Na

成都医学院第一附属医院呼吸与危重症医学科（四川成都 610500）;

Corresponding author：

HUANG Na, Email: 717308813@qq.com

Keywords：

DOI：

10.7507/1671-6205.202201014

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： XIANG Liping, YANG Yi, HUANG Na. 溶瘤病毒在肺癌治疗中的研究进展. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(5): 374-380. doi: 10.7507/1671-6205.202201014 Copy

1.	Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet, 2021, 398(10299): 535-554.
2.	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3.	Marx A, Chan JKC, Chalabreysse L, et al. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. J Thorac Oncol, 2022, 17(2): 200-213.
4.	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
5.	Feola S, Russo S, Ylösmäki E, et al. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther, 2021, 236: 108103.
6.	Wei D, Xu J, Liu XY, et al. Fighting cancer with viruses: oncolytic virus therapy in China. Hum Gene Ther, 2018, 29(2): 151-159.
7.	Thomas S, Kuncheria L, Roulstone V, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer, 2019, 7(1): 214.
8.	Sugawara K, Iwai M, Ito H, et al. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Mol Ther Oncolytics, 2021, 22: 129-142.
9.	Lawler SE, Speranza MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol, 2017, 3(6): 841-849.
10.	Angarita FA, Acuna SA, Ottolino-Perry K, et al. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med, 2013, 19(6): 378-392.
11.	Masemann D, Meissner R, Schied T, et al. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune-checkpoint inhibitors against IC-resistant lung cancers. Oncoimmunology, 2021, 10(1): 1885778.
12.	Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol, 2020, 13(1): 84.
13.	Mantwill K, Klein FG, Wang D, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci, 2021, 22(19): 10522.
14.	Zhang R, Cui YX, Guan X, et al. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front Oncol, 2021, 11: 752504.
15.	Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol, 2020, 6(3): 402-408.
16.	Streby KA, Geller JI, Currier MA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res, 2017, 23(14): 3566-3574.
17.	Uche IK, Kousoulas KG, Rider PJF. The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment. Viruses, 2021, 13(7): 1200.
18.	Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer, 2019, 7(1): 6.
19.	Mell LK, Brumund KT, Daniels GA, et al. Phase Ⅰ trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res, 2017, 23(19): 5696-5702.
20.	Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel), 2020, 12(12): 3552.
21.	Islam S, Espitia CM, Persky DO, et al. Targeting JAK/STAT signaling antagonizes resistance to oncolytic reovirus therapy driven by prior infection with HTLV-1 in models of T-cell lymphoma. Viruses, 2021, 13(7): 1406.
22.	Mahalingam D, Wilkinson GA, Eng KH, et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ⅰb study. Clin Cancer Res, 2020, 26(1): 71-81.
23.	Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol, 2018, 18(8): 498-513.
24.	Hamid O, Hoffner B, Gasal E, et al. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother, 2017, 66(10): 1249-1264.
25.	Bai Y, Hui P, Du XY, et al. Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer, 2019, 10(5): 1031-1035.
26.	Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol, 2020, 65: 25-36.
27.	de Graaf JF, de Vor L, Fouchier RAM, et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine Growth Factor Rev, 2018, 41: 28-39.
28.	Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest, 2018, 128(4): 1258-1260.
29.	Hutzen B, Bid HK, Houghton PJ, et al. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer, 2014, 14: 206.
30.	Hashemi Goradel N, Ghiyami-Hour F, Jahangiri S, et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J Cell Physiol, 2018, 233(4): 2902-2910.
31.	Goradel NH, Asghari MH, Moloudizargari M, et al. Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol, 2017, 335: 56-63.
32.	Breitbach CJ, Arulanandam R, De Silva N, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res, 2013, 73(4): 1265-1275.
33.	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830.
34.	Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol, 2020, 38(14): 1505-1517.
35.	Yang YP, Wang ZH, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous nsclc: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol, 2020, 15(10): 1636-1646.
36.	Bullard BL, Corder BN, Weaver EA. Species D adenoviruses as oncolytic viral vectors. Viruses, 2020, 12(12): 1399.
37.	Garofalo M, Saari H, Somersalo P, et al. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release, 2018, 283: 223-234.
38.	Sakhawat A, Liu Y, Ma L, et al. Upregulation of coxsackie adenovirus receptor sensitizes cisplatin-resistant lung cancer cells to CRAd-induced inhibition. J Cancer, 2017, 8(8): 1425-1432.
39.	Yang Y, Xu HN, Huang WD, et al. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med, 2015, 19(5): 915-923.
40.	Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res, 2012, 72(10): 2609-2621.
41.	Deng HY, Liu HT, de Silva T, et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol Ther Oncolytics, 2019, 14: 266-278.
42.	Liu HT, Xue YC, Deng HY, et al. MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer. Mol Ther Oncolytics, 2020, 16: 207-218.
43.	Cai LG, Liu ZY. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med, 2020, 9(14): 5210-5220.
44.	Lv CW, Su QS, Liang YP, et al. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem Biophys Res Commun, 2016, 476(1): 21-28.
45.	Hu JQ, Wang HY, Gu JF, et al. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Acta Biochim Biophys Sin (Shanghai), 2018, 50(10): 1018-1027.
46.	Weibel S, Hofmann E, Basse-Luesebrink TC, et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med, 2013, 11: 106.
47.	Hofmann E, Weibel S, Szalay AA. Combination treatment with oncolytic vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med, 2014, 12: 197.
48.	Masemann D, Köther K, Kuhlencord M, et al. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology, 2018, 7(5): e1423171.
49.	Villalona-Calero MA, Lam E, Otterson GA, et al. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer, 2016, 122(6): 875-883.
50.	Patel MR, Dash A, Jacobson BA, et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther, 2019, 26(11-12): 411-418.
51.	Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res, 2000, 60(9): 2497-2503.
52.	Ganesh S, Gonzalez-Edick M, Gibbons D, et al. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res, 2008, 14(12): 3933-3941.
53.	Fu XP, Tao LH, Wu WF, et al. Arming HSV-based oncolytic viruses with the ability to redirect the host's innate antiviral immunity to attack tumor cells. Mol Ther Oncolytics, 2020, 19: 33-46.
54.	Yoon AR, Hong J, Li Y, et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res, 2019, 79(17): 4503-4514.
55.	Josiah DT, Zhu D, Dreher F, et al. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther, 2010, 18(2): 377-385.
56.	Perkins D. Targeting apoptosis in neurological disease using the herpes simplex virus. J Cell Mol Med, 2002, 6(3): 341-356.
57.	Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther, 2007, 15(4): 651-659.
58.	Li LZ, Liu SX, Han DD, et al. Delivery and biosafety of oncolytic virotherapy. Front Oncol, 2020, 10: 475.
59.	Li ZB, Jiang ZJ, Zhang YX, et al. Efficacy and safety of oncolytic viruses in randomized controlled trials: a systematic review and meta-analysis. Cancers (Basel), 2020, 12(6): 1416.

1. Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet, 2021, 398(10299): 535-554.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3. Marx A, Chan JKC, Chalabreysse L, et al. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. J Thorac Oncol, 2022, 17(2): 200-213.
4. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
5. Feola S, Russo S, Ylösmäki E, et al. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther, 2021, 236: 108103.
6. Wei D, Xu J, Liu XY, et al. Fighting cancer with viruses: oncolytic virus therapy in China. Hum Gene Ther, 2018, 29(2): 151-159.
7. Thomas S, Kuncheria L, Roulstone V, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer, 2019, 7(1): 214.
8. Sugawara K, Iwai M, Ito H, et al. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Mol Ther Oncolytics, 2021, 22: 129-142.
9. Lawler SE, Speranza MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol, 2017, 3(6): 841-849.
10. Angarita FA, Acuna SA, Ottolino-Perry K, et al. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med, 2013, 19(6): 378-392.
11. Masemann D, Meissner R, Schied T, et al. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune-checkpoint inhibitors against IC-resistant lung cancers. Oncoimmunology, 2021, 10(1): 1885778.
12. Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol, 2020, 13(1): 84.
13. Mantwill K, Klein FG, Wang D, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci, 2021, 22(19): 10522.
14. Zhang R, Cui YX, Guan X, et al. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front Oncol, 2021, 11: 752504.
15. Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol, 2020, 6(3): 402-408.
16. Streby KA, Geller JI, Currier MA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res, 2017, 23(14): 3566-3574.
17. Uche IK, Kousoulas KG, Rider PJF. The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment. Viruses, 2021, 13(7): 1200.
18. Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer, 2019, 7(1): 6.
19. Mell LK, Brumund KT, Daniels GA, et al. Phase Ⅰ trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res, 2017, 23(19): 5696-5702.
20. Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel), 2020, 12(12): 3552.
21. Islam S, Espitia CM, Persky DO, et al. Targeting JAK/STAT signaling antagonizes resistance to oncolytic reovirus therapy driven by prior infection with HTLV-1 in models of T-cell lymphoma. Viruses, 2021, 13(7): 1406.
22. Mahalingam D, Wilkinson GA, Eng KH, et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ⅰb study. Clin Cancer Res, 2020, 26(1): 71-81.
23. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol, 2018, 18(8): 498-513.
24. Hamid O, Hoffner B, Gasal E, et al. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother, 2017, 66(10): 1249-1264.
25. Bai Y, Hui P, Du XY, et al. Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer, 2019, 10(5): 1031-1035.
26. Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol, 2020, 65: 25-36.
27. de Graaf JF, de Vor L, Fouchier RAM, et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine Growth Factor Rev, 2018, 41: 28-39.
28. Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest, 2018, 128(4): 1258-1260.
29. Hutzen B, Bid HK, Houghton PJ, et al. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer, 2014, 14: 206.
30. Hashemi Goradel N, Ghiyami-Hour F, Jahangiri S, et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J Cell Physiol, 2018, 233(4): 2902-2910.
31. Goradel NH, Asghari MH, Moloudizargari M, et al. Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol, 2017, 335: 56-63.
32. Breitbach CJ, Arulanandam R, De Silva N, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res, 2013, 73(4): 1265-1275.
33. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830.
34. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol, 2020, 38(14): 1505-1517.
35. Yang YP, Wang ZH, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous nsclc: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol, 2020, 15(10): 1636-1646.
36. Bullard BL, Corder BN, Weaver EA. Species D adenoviruses as oncolytic viral vectors. Viruses, 2020, 12(12): 1399.
37. Garofalo M, Saari H, Somersalo P, et al. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release, 2018, 283: 223-234.
38. Sakhawat A, Liu Y, Ma L, et al. Upregulation of coxsackie adenovirus receptor sensitizes cisplatin-resistant lung cancer cells to CRAd-induced inhibition. J Cancer, 2017, 8(8): 1425-1432.
39. Yang Y, Xu HN, Huang WD, et al. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med, 2015, 19(5): 915-923.
40. Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res, 2012, 72(10): 2609-2621.
41. Deng HY, Liu HT, de Silva T, et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol Ther Oncolytics, 2019, 14: 266-278.
42. Liu HT, Xue YC, Deng HY, et al. MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer. Mol Ther Oncolytics, 2020, 16: 207-218.
43. Cai LG, Liu ZY. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med, 2020, 9(14): 5210-5220.
44. Lv CW, Su QS, Liang YP, et al. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem Biophys Res Commun, 2016, 476(1): 21-28.
45. Hu JQ, Wang HY, Gu JF, et al. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Acta Biochim Biophys Sin (Shanghai), 2018, 50(10): 1018-1027.
46. Weibel S, Hofmann E, Basse-Luesebrink TC, et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med, 2013, 11: 106.
47. Hofmann E, Weibel S, Szalay AA. Combination treatment with oncolytic vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med, 2014, 12: 197.
48. Masemann D, Köther K, Kuhlencord M, et al. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology, 2018, 7(5): e1423171.
49. Villalona-Calero MA, Lam E, Otterson GA, et al. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer, 2016, 122(6): 875-883.
50. Patel MR, Dash A, Jacobson BA, et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther, 2019, 26(11-12): 411-418.
51. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res, 2000, 60(9): 2497-2503.
52. Ganesh S, Gonzalez-Edick M, Gibbons D, et al. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res, 2008, 14(12): 3933-3941.
53. Fu XP, Tao LH, Wu WF, et al. Arming HSV-based oncolytic viruses with the ability to redirect the host's innate antiviral immunity to attack tumor cells. Mol Ther Oncolytics, 2020, 19: 33-46.
54. Yoon AR, Hong J, Li Y, et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res, 2019, 79(17): 4503-4514.
55. Josiah DT, Zhu D, Dreher F, et al. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther, 2010, 18(2): 377-385.
56. Perkins D. Targeting apoptosis in neurological disease using the herpes simplex virus. J Cell Mol Med, 2002, 6(3): 341-356.
57. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther, 2007, 15(4): 651-659.
58. Li LZ, Liu SX, Han DD, et al. Delivery and biosafety of oncolytic virotherapy. Front Oncol, 2020, 10: 475.
59. Li ZB, Jiang ZJ, Zhang YX, et al. Efficacy and safety of oncolytic viruses in randomized controlled trials: a systematic review and meta-analysis. Cancers (Basel), 2020, 12(6): 1416.

Previous Article
1-磷酸鞘氨醇在脓毒症诊疗中的应用前景

Chinese Journal of Respiratory and Critical Care Medicine

溶瘤病毒在肺癌治疗中的研究进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content